CytomX Therapeutics appoints Marion McCourt to board
Ms. McCourt has more than two decades of operational and commercial leadership experience at several of the world's most innovative biopharmaceutical companies.
Ms. McCourt most recently served as Chief Operating Officer at Medivation until the company’s acquisition by Pfizer in September 2016.
Prior to joining Medivation in February 2016, Ms. McCourt served as Vice President of U.S. Commercial Operations at Amgen Inc.
Prior to that, she also served as Vice President and General Manager of Amgen's Bone Health & Primary Care Business Unit.
Before joining Amgen, Ms. McCourt held numerous positions of increasing responsibility over a twelve-year career at AstraZeneca.
There, she most recently served as Chief Operating Officer of AstraZeneca U.S., where she was responsible for all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations and corporate affairs.
Ms. McCourt holds a B.S. degree in Biology from Lafayette College. ■
LATEST MOVES FROM California
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
- Lombard Medical appoints Kurt Lemvigh as CEO
- CareDx appoints Michael Bell as CFO
- Visa appoints John F. Lundgren as director
More inside POST